A CMS advisory panel concluded that high doses of erythropoiesis-stimulating agents used to treat anemia increased heart risks in patients with chronic kidney disease. The panel was convened to determine whether updated guidelines are necessary on the use of Johnson & Johnson's Procrit and Amgen's Aranesp and Epogen.

Full Story:

Related Summaries